Edition:
India

CymaBay Therapeutics Inc (CBAY.OQ)

CBAY.OQ on NASDAQ Stock Exchange Capital Market

10.20USD
2:29am IST
Change (% chg)

$0.06 (+0.59%)
Prev Close
$10.14
Open
$10.15
Day's High
$10.48
Day's Low
$10.04
Volume
180,560
Avg. Vol
180,818
52-wk High
$10.48
52-wk Low
$1.46

Latest Key Developments (Source: Significant Developments)

Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cymabay Therapeutics Inc ::CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA.  Full Article

CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln
Saturday, 30 Dec 2017 

Dec 29 (Reuters) - CymaBay Therapeutics Inc ::CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.  Full Article

CymaBay reports Q3 loss per share $0.21
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - CymaBay Therapeutics Inc ::CymaBay reports third quarter 2017 financial results and corporate updates.Q3 loss per share $0.21.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.CymaBay Therapeutics - ‍cash, cash equivalents and marketable securities totaled $102.2 million at end of Q3 of 2017, compared to $17.0 million at Dec 31, 2016​.CymaBay Therapeutics Inc - ‍existing cash expected to fund operations into 2019​.  Full Article

Cymabay Therapeutics names Sujal Shah CEO
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cymabay Therapeutics Inc :Cymabay announces the appointment of Sujal Shah as president and chief executive officer.Cymabay Therapeutics Inc says ‍sujal Shah has been serving as interim president and chief executive officer since March 2017​.  Full Article

Cymabay to deliver interim results from ongoing phase 2 study of Seladelpar at AASLD 2017
Monday, 9 Oct 2017 

Oct 9 (Reuters) - Cymabay Therapeutics Inc :Cymabay announces oral late-breaking presentation of interim results from an ongoing Phase 2 study of patients with primary biliary cholangitis at the AASLD 2017 Liver Meeting.Cymabay Therapeutics - ‍interim Phase 2 study results demonstrate potential for superior efficacy, better tolerability over existing second-line therapy​.  Full Article

Cymabay reports second quarter 2016 financial results
Wednesday, 10 Aug 2016 

Cymabay Therapeutics Inc : Q2 loss per share $0.30 . Cymabay reports second quarter 2016 financial results .Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article

Cymabay qtrly loss per share $0.29
Thursday, 12 May 2016 

Cymabay Therapeutics Inc : Qtrly loss per share $0.29 .Cymabay reports first quarter 2016 financial results.  Full Article

BRIEF-Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America

* CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA Source text for Eikon: Further company coverage: